EC has granted marketing authorisation to BridgeBio Pharma’s acoramidis under the Beyonttra brand name for treating ATTR-CM.

Travere’s stock price climbed by 14% following the announcement it will seek an FDA label expansion for Filspari.

The US Food and Drug Administration (FDA) has approved SpringWorks Therapeutics’ Gomekli (mirdametinib) to treat ...

Health Canada has approved MSD’s anti-programmed cell death protein 1 (PD-1) therapy Keytruda for treating adults with ...

The UK announced the funding at the AI Action Summit in Paris where it abstained from signing a declaration on an inclusive ...

The World Health Organization and St Jude Children's Research Hospital have kicked off a programme to distribute cancer ...

Grace has announced the initial closing of a financing round, securing almost $15m, for funding pre-commercial development of ...

Controversy surrounded Hims & Hers’ commercial, called ‘Sick of the System’, in the lead up to America’s biggest sporting ...

Bio-Thera Solutions has signed an exclusive licence and commercialisation agreement with Intas Pharmaceuticals for BAT2506 in ...

Eli Lilly is paying up to $630m for a Phase I MASH candidate from OliX Pharmaceuticals, diversifying its pipeline with an RNA ...

Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...

China's NMPA has granted approval for Keymed Biosciences’ supplemental NDA of Stapokibart to treat seasonal allergic rhinitis ...